Safety of proline-specific oligopeptidase as a novel food pursuant to Regulation (EC) No 258/97: (Scientific Opinion)

Publikation: Bidrag til tidsskriftTidsskriftartikelRådgivningfagfællebedømt

Standard

Safety of proline-specific oligopeptidase as a novel food pursuant to Regulation (EC) No 258/97 : (Scientific Opinion). / EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA).

I: E F S A Journal, Bind 15, Nr. 2, 4681, 15.02.2017.

Publikation: Bidrag til tidsskriftTidsskriftartikelRådgivningfagfællebedømt

Harvard

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2017, 'Safety of proline-specific oligopeptidase as a novel food pursuant to Regulation (EC) No 258/97: (Scientific Opinion)', E F S A Journal, bind 15, nr. 2, 4681. https://doi.org/10.2903/j.efsa.2017.4681

APA

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2017). Safety of proline-specific oligopeptidase as a novel food pursuant to Regulation (EC) No 258/97: (Scientific Opinion). E F S A Journal, 15(2), [4681]. https://doi.org/10.2903/j.efsa.2017.4681

Vancouver

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Safety of proline-specific oligopeptidase as a novel food pursuant to Regulation (EC) No 258/97: (Scientific Opinion). E F S A Journal. 2017 feb 15;15(2). 4681. https://doi.org/10.2903/j.efsa.2017.4681

Author

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). / Safety of proline-specific oligopeptidase as a novel food pursuant to Regulation (EC) No 258/97 : (Scientific Opinion). I: E F S A Journal. 2017 ; Bind 15, Nr. 2.

Bibtex

@article{a62dd06c2f994ebcab67c3413c305a1c,
title = "Safety of proline-specific oligopeptidase as a novel food pursuant to Regulation (EC) No 258/97: (Scientific Opinion)",
abstract = "Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on proline-specific oligopeptidase (Tolerase{\circledR} G) as a novel food ingredient submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council, taking into account the comments and objections of a scientific nature raised by Member States. The novel food is an enzyme preparation of prolyl-oligopeptidase produced with a genetically modified Aspergillus niger self clone strain. The target population is the general adult population. The results from a bacterial reverse mutation test and of an in vitro chromosome aberration test did not indicate genotoxicity. The Panel considers that the reported effects observed in a 90-day rat study are treatment-related effects and can be attributed to the higher energy consumption by these animals. Taking into account the intended maximum use level for Tolerase{\circledR} G, its daily consumption would correspond to 2,746 mg TOS/person or to 39.2 mg TOS/kg body weight (bw) per day, when considering a default body weight of 70 kg for an adult person. The margin between this value and the dose in the rats, which caused effects attributable to the excess energy intake, is approximately 45. Noting this margin, the Panel considers that it is unlikely that such effects would occur in human at the intended use levels. The Panel concludes that the NF, Tolerase{\circledR} G, is safe for the intended use at the intended use level.",
keywords = "Faculty of Science, Novel food, Proline-specific oligopeptidase, Tolerase{\circledR} G, Ingredient, Safety",
author = "{EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)} and Sj{\"o}din, {Anders Mikael}",
note = "EFSA 2017 4681",
year = "2017",
month = "2",
day = "15",
doi = "10.2903/j.efsa.2017.4681",
language = "English",
volume = "15",
journal = "E F S A Journal",
issn = "1831-4732",
publisher = "European Food Safety Authority (E F S A)",
number = "2",

}

RIS

TY - JOUR

T1 - Safety of proline-specific oligopeptidase as a novel food pursuant to Regulation (EC) No 258/97

T2 - (Scientific Opinion)

AU - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

AU - Sjödin, Anders Mikael

N1 - EFSA 2017 4681

PY - 2017/2/15

Y1 - 2017/2/15

N2 - Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on proline-specific oligopeptidase (Tolerase® G) as a novel food ingredient submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council, taking into account the comments and objections of a scientific nature raised by Member States. The novel food is an enzyme preparation of prolyl-oligopeptidase produced with a genetically modified Aspergillus niger self clone strain. The target population is the general adult population. The results from a bacterial reverse mutation test and of an in vitro chromosome aberration test did not indicate genotoxicity. The Panel considers that the reported effects observed in a 90-day rat study are treatment-related effects and can be attributed to the higher energy consumption by these animals. Taking into account the intended maximum use level for Tolerase® G, its daily consumption would correspond to 2,746 mg TOS/person or to 39.2 mg TOS/kg body weight (bw) per day, when considering a default body weight of 70 kg for an adult person. The margin between this value and the dose in the rats, which caused effects attributable to the excess energy intake, is approximately 45. Noting this margin, the Panel considers that it is unlikely that such effects would occur in human at the intended use levels. The Panel concludes that the NF, Tolerase® G, is safe for the intended use at the intended use level.

AB - Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on proline-specific oligopeptidase (Tolerase® G) as a novel food ingredient submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council, taking into account the comments and objections of a scientific nature raised by Member States. The novel food is an enzyme preparation of prolyl-oligopeptidase produced with a genetically modified Aspergillus niger self clone strain. The target population is the general adult population. The results from a bacterial reverse mutation test and of an in vitro chromosome aberration test did not indicate genotoxicity. The Panel considers that the reported effects observed in a 90-day rat study are treatment-related effects and can be attributed to the higher energy consumption by these animals. Taking into account the intended maximum use level for Tolerase® G, its daily consumption would correspond to 2,746 mg TOS/person or to 39.2 mg TOS/kg body weight (bw) per day, when considering a default body weight of 70 kg for an adult person. The margin between this value and the dose in the rats, which caused effects attributable to the excess energy intake, is approximately 45. Noting this margin, the Panel considers that it is unlikely that such effects would occur in human at the intended use levels. The Panel concludes that the NF, Tolerase® G, is safe for the intended use at the intended use level.

KW - Faculty of Science

KW - Novel food

KW - Proline-specific oligopeptidase

KW - Tolerase® G

KW - Ingredient

KW - Safety

U2 - 10.2903/j.efsa.2017.4681

DO - 10.2903/j.efsa.2017.4681

M3 - Journal article

VL - 15

JO - E F S A Journal

JF - E F S A Journal

SN - 1831-4732

IS - 2

M1 - 4681

ER -

ID: 188402600